A survey of organisations providing specialist palliative care services to care homes highlights the work they do and the challenges they face. Commissioned by Public Health England, the survey examines the role of specialist palliative care in providing support to care homes in England.
NICE has approved liver cancer drug, sorafenib for routine NHS use. Three-quarters of drugs covered by the cancer drugs fund (CDF) have now been approved without a negative decision. Sorafenib is eighteenth on the list of 24 drugs NICE was asked to approve for the CDF.
NICE has published new guidance on the use of drugs called bisphosphonates for preventing bone fractures in people at increased risk.
The new guidance links a person’s risk of having a bone fracture with the point at which treatment should be started, based on cost effectiveness.
It recommends treatment with oral bisphosphonate drugs alendronic acid, ibandronic acid and risedronate sodium as options for people who have at least a 1% risk of a bone fracture within the next 10 years.
This report argues that the NHS could see a significant reduction in the amount of people unnecessarily admitted for emergency general surgery if more acute hospitals introduced consultant-led surgical assessments at their ‘front door’. The analysis estimates that this change could lead to up to 30% fewer general surgery emergency admissions a year saving over £100m.